Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J's Apalutamide, Astellas/Pfizer's Xtandi On Par For Non-Metastatic Prostate Cancer

Executive Summary

Phase III data at ASCO GU meeting impress, but raise questions about safety in new non-metastatic CRPC indication – rash, fractures and falls for Erleada (apalutamide) and unexplained deaths after termination of treatment for Xtandi (enzalutamide).


Related Content

Bayer Sees Room For Third-To-Market Darolutamide In Prostate Cancer
Pfizer, Astellas Accelerate Xtandi's Timeline In Early Prostate Cancer
Keeping Track: Tpoxx Wins Green Light For Smallpox, Submissions Galore, And A Broader Approval For Xtandi
At J&J, Oncology Closes In On Immunology As The Leading Pharma Franchise
Keeping Track: Ilumya, Adcetris Approved; Xtandi Priority Reviewed; Azedra Goal Date Extended
J&J Shows Grace Under Pressure From Biosimilars And Other Threats
PTAB Clears Path For Earlier Generic Zytiga Launch
Pfizer Poised To PROSPER From Xtandi In Expanded Indication


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts